Document is current
Any future updates will be listed below
-
Authors
Hu, Zhe-Yu
Liu, Binliang
Xie, Ning
Yang, Xiaohong
Liu, Liping
Xiao, Huawu
Li, Jing
Wu, Hui
Gao, Jianxiang
Lu, Jun
Hu, Xuming
Cao, Min
Shui, Zhengrong
Tian, Can
Ouyang, Quchang
-
Funding
Funding for this research was provided by:
Pfizer GMG-2021-ONC-L_China Medical Education Project (GMG-2021-ONC-L)
Hunan Cancer Hospital Climb Plan (ZX2021005)
Hunan Provincial Natural Science Foundation of China (2023JJ60464)
Major Scientific Research Project of Chinese Key Clinical Specialty (Z2023046)
- License Information
-
More Information
Article History
Received: 20 September 2023
Accepted: 19 July 2024
First Online: 30 July 2024
Declarations
:
: The study was approved by the Ethics Committee at the Hunan Cancer Hospital / The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University. Informed consent was obtained from each patient prior to study onset.
: Not Applicable.
: The authors declare no competing interests.
